Article

New treatments for neuromuscular disease: Optimism and obstacles

Professor of Experimental Myology, Institute of Human Genetics, University of Newcastle, Newcastle upon Tyne, UK.
Neurotherapeutics (Impact Factor: 3.88). 11/2008; 5(4):497-8. DOI: 10.1016/j.nurt.2008.08.010
Source: PubMed
0 Followers
 · 
60 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The neuromuscular junction (NMJ) is a complex structure that efficiently communicates the electrical impulse from the motor neuron to the skeletal muscle to induce muscle contraction. Genetic and autoimmune disorders known to compromise neuromuscular transmission are providing further insights into the complexities of NMJ function. Congenital myasthenic syndromes (CMSs) are a genetically and phenotypically heterogeneous group of rare hereditary disorders affecting neuromuscular transmission. The understanding of the molecular basis of the different types of CMSs has evolved rapidly in recent years. Mutations were first identified in the subunits of the nicotinic acetylcholine receptor (AChR), but now mutations in ten different genes - encoding post-, pre- or synaptic proteins - are known to cause CMSs. Pathogenic mechanisms leading to an impaired neuromuscular transmission modify AChRs or endplate structure or lead to decreased acetylcholine synthesis and release. However, the genetic background of many CMS forms is still unresolved. A precise molecular classification of CMS type is of paramount importance for the diagnosis, counselling and therapy of a patient, as different drugs may be beneficial or deleterious depending on the molecular background of the particular CMS.
    Expert Reviews in Molecular Medicine 02/2007; 9(22):1-20. DOI:10.1017/S1462399407000427 · 5.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The progress made in vector technology and preclinical evaluation of molecular and gene therapy for inherited muscle diseases led to initiation of the first clinical trials using plasmid and adeno-associated virus vectors, as well as antisense oligonucleotides. The scope of this review is to discuss the current status of gene therapy for muscular dystrophy and to highlight recent advances in viral, cell-based as well as molecular therapies.
    Drug News & Perspectives 01/2007; 20(6):357-63. DOI:10.1358/dnp.2007.20.6.1138159 · 3.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prednisone improves strength in Duchenne dystrophy and changes the natural history of the disease. We studied the in vivo effects of prednisone (0.75 mg.kg-1.day-1) on muscle and whole body protein metabolism in six patients with Duchenne dystrophy and three patients with Becker dystrophy. Patients were admitted to the Clinical Research Center for study and consumed a constant flesh-free diet. Strength was measured by manual and quantitative muscle testing. Fractional muscle protein breakdown was estimated by the ratio of 3-methylhistidine to creatinine excretion determined in three consecutive 24-h urine collections. Whole body protein kinetics were studied in the postabsorptive state using a primed continuous infusion of L-[1-13C]leucine. Fractional muscle protein synthesis was determined from tracer incorporation into noncollagen muscle protein obtained by needle biopsy. After 6-8 wk of prednisone treatment, average muscle strength increased by 15% (P < 0.04), and 24-h creatinine excretion (an index of muscle mass) increased by 21% (P = 0.002). 3-Methylhistidine excretion decreased by 10%, but the change was not statistically significant. The ratio of 3-methylhistidine to creatinine excretion decreased by 26% (P < 0.04). Fractional muscle protein synthesis and whole body protein synthesis and breakdown did not change significantly. We conclude that the beneficial effect of prednisone on strength in Duchenne dystrophy appears to be associated with an increase in muscle mass, which may be mediated by inhibition of muscle proteolysis rather than stimulation of muscle protein synthesis.
    The American journal of physiology 01/1995; 268(1 Pt 1):E67-74. · 3.28 Impact Factor

Preview

Download
0 Downloads
Available from